FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): February 3, 2025

BIOADAPTIVES, INC.

(Exact Name of Registrant as Specified in its Charter)

Delaware

000-54949

46-2592228

(State or Other Jurisdiction

of Incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

2620 Regatta Drive, Suite 102

Las Vegas, Nevada 89128

(Address of Principal Executive Office) (Zip Code)

(702) 659-8829

Registrant's telephone number, including area code:

N/A

(former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02. Appointments of Mr. Mark Frissora to Board of Directors and Mr. Reed Harris to Advisory Board

On February 3, 2025 , the Company appointed Mr. Mark Frissora to its Board of Directors. A press release was issued to this effect, which is incorporated by reference to 99.1a to this Current Report on Form 8-K.

On February 6, 2025, the Company appointed Mr. Reed Harris to its Advisory Board. A press release was issued to this effect, which is incorporated by reference to 99.1b to this Current Report on Form 8K.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number		Exhibit Description

99.1a		Press Release dated February 3, 2025

99.1b		Press Release dated February 6. 2025

SIGNATURE

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

February 7, 2025.	BioAdaptives, Inc.

	/s/ James Keener
	James Keener, CEO

BIOADAPTIVES, INC. 8-K